Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler.

Sasaki H, Okuda K, Kawano O, Endo K, Yukiue H, Yokoyama T, Yano M, Fujii Y.

Oncol Rep. 2007 Sep;18(3):623-8.

PMID:
17671710
2.

The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.

Izar B, Zhou H, Heist RS, Azzoli CG, Muzikansky A, Scribner EE, Bernardo LA, Dias-Santagata D, Iafrate AJ, Lanuti M.

J Thorac Oncol. 2014 Sep;9(9):1363-9. doi: 10.1097/JTO.0000000000000266.

3.

Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.

Wen YS, Cai L, Zhang XW, Zhu JF, Zhang ZC, Shao JY, Zhang LJ.

Medicine (Baltimore). 2014 Dec;93(29):e296. doi: 10.1097/MD.0000000000000296.

4.

Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.

Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T.

J Thorac Oncol. 2009 Jan;4(1):22-9. doi: 10.1097/JTO.0b013e3181914111.

5.

Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.

Serizawa M, Koh Y, Kenmotsu H, Isaka M, Murakami H, Akamatsu H, Mori K, Abe M, Hayashi I, Taira T, Maniwa T, Takahashi T, Endo M, Nakajima T, Ohde Y, Yamamoto N.

Cancer. 2014 May 15;120(10):1471-81. doi: 10.1002/cncr.28604. Epub 2014 Apr 3.

6.

Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer.

Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M, Fujii Y.

J Thorac Oncol. 2011 Jan;6(1):15-20. doi: 10.1097/JTO.0b013e31820594f0.

7.

Characteristics of lung cancers harboring NRAS mutations.

Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA Jr, Pao W.

Clin Cancer Res. 2013 May 1;19(9):2584-91. doi: 10.1158/1078-0432.CCR-12-3173. Epub 2013 Mar 20.

8.

EGFR and KRAS mutations in patients with adenocarcinoma of the lung.

Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH.

Korean J Intern Med. 2009 Mar;24(1):48-54. doi: 10.3904/kjim.2009.24.1.43.

9.

Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura.

Raparia K, Villa C, Raj R, Cagle PT.

Arch Pathol Lab Med. 2015 Feb;139(2):189-93. doi: 10.5858/arpa.2013-0759-OA. Epub 2014 Apr 2.

PMID:
24694341
10.

Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma.

Sunaga N, Kaira K, Tomizawa Y, Shimizu K, Imai H, Takahashi G, Kakegawa S, Ohtaki Y, Nagashima T, Kasahara N, Kawashima O, Hisada T, Saito R, Yamada M.

Br J Cancer. 2014 Apr 15;110(8):2047-53. doi: 10.1038/bjc.2014.110. Epub 2014 Feb 27.

11.

EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.

Sasaki H, Endo K, Konishi A, Takada M, Kawahara M, Iuchi K, Matsumura A, Okumura M, Tanaka H, Kawaguchi T, Shimizu T, Takeuchi H, Yano M, Fukai I, Fujii Y.

Clin Cancer Res. 2005 Apr 15;11(8):2924-9.

12.

The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma.

Villaruz LC, Socinski MA, Cunningham DE, Chiosea SI, Burns TF, Siegfried JM, Dacic S.

Cancer. 2013 Jun 15;119(12):2268-74. doi: 10.1002/cncr.28039. Epub 2013 Mar 22.

13.

Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma.

Shibata T, Hanada S, Kokubu A, Matsuno Y, Asamura H, Ohta T, Sakamoto M, Hirohashi S.

Cancer Sci. 2007 Jul;98(7):985-91. Epub 2007 Apr 23.

14.

Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma.

Vagaja NN, Parry J, McCallum D, Thomas MA, Bentel JM.

J Clin Pathol. 2015 Aug;68(8):657-60. doi: 10.1136/jclinpath-2015-202969. Epub 2015 Apr 29.

PMID:
25926041
15.

Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.

Vatan O, Bilaloglu R, Tunca B, Cecener G, Gebitekin C, Egeli U, Yakut T, Urer N.

Tumori. 2007 Sep-Oct;93(5):473-7.

16.

KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.

Nadal E, Chen G, Prensner JR, Shiratsuchi H, Sam C, Zhao L, Kalemkerian GP, Brenner D, Lin J, Reddy RM, Chang AC, Capellà G, Cardenal F, Beer DG, Ramnath N.

J Thorac Oncol. 2014 Oct;9(10):1513-22. doi: 10.1097/JTO.0000000000000305.

17.

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.

Calles A, Sholl LM, Rodig SJ, Pelton AK, Hornick JL, Butaney M, Lydon C, Dahlberg SE, Oxnard GR, Jackman DM, Jänne PA.

Clin Cancer Res. 2015 Jun 15;21(12):2851-60. doi: 10.1158/1078-0432.CCR-14-3112. Epub 2015 Mar 3.

18.

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.

Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, Riely GJ.

J Thorac Oncol. 2015 Mar;10(3):431-7. doi: 10.1097/JTO.0000000000000432.

19.

The status of KRAS mutations in patients with non-small cell lung cancers from mainland China.

Li M, Liu L, Liu Z, Yue S, Zhou L, Zhang Q, Cheng S, Li RW, Smith PN, Lu S.

Oncol Rep. 2009 Nov;22(5):1013-20.

PMID:
19787214
20.

MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.

Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, Guerin E, Legrain M, Mennecier B, Wihlm JM, Massard G, Quoix E, Oudet P, Gaub MP.

J Thorac Oncol. 2008 Apr;3(4):331-9. doi: 10.1097/JTO.0b013e318168d9d4.

Supplemental Content

Support Center